Mass. biotech: FDA to review experimental cancer drug after two rejections, 200+ layoffs

Replimune gutted its entire sales and marketing team after the FDA rejected its melanoma treatment for a second time. Now the Woburn biotech is getting a third shot at approval — with a public FDA…